Medical/Scientific/LiaisonField/based/KOL/Speaker/Development/Identification/mapping/of/KOLs/Develop/professional/relationships/with/the/targeting/KOLs/and/build/advocacy/and/gain/contributions/of/KOL/decision/makers/Proactively/Visit/Track/analyze/and/reports/targeting/KOLs/advocacy/contribution/and/publication/status/in/required/system/and/KOL/management/tool/as/appropriate/Provide/and/discuss/scientific/information/and/data/regarding/new/launched/products/to/healthcare/professionals/to/ensure/quality/and/accuracy/of/key/medical/and/scientific/information/on/new/treatment/options/by/face/to/face/visits/speaker/training/and/scientific/communications/Scientific/support/of/speaker/training/activities/in/the/region/with/timely/feedback/Information/Management/and/Meeting/Events/May/function/as/the/Novartis/medical/speaker/to/present/at/Novartis/Society/sponsored/activities/for/up/to/date/data/based/scientific/and/clinical/information/on/Novartis/product/s/Liaise/and/provide/up/to/date/medical/support/to/facilitate/listing/of/products/in/medical/guidelines/RDL/formularies/as/appropriate/Participate/in/cross/functional/meetings/as/appropriate/and/sharing/feedback/of/targeting/KOLs/advocacy/and/contribution/Prepare/and/tailor/speaker/slides/in/alignment/with/NP4/and/Medical/strategies/Manage/unsolicited/requests/objections/comply/with/NP4/and/China/legal/and/regulatory/requirements/Clinical/Trials/and/Medical/Affairs/Studies/Contribute/to/the/identification/and/recommendation/of/appropriate/KOL/involvement/and/participation/in/Novartis/sponsored/clinical/trials/PMS/Phase/III/and/Phase/IV/studies/from/assigned/region/Conduct/or/Coordinate/third/party/trials/animal/studies/registry/or/epidemiology/programs/in/assigned/region/and/operation/follow/up/the/above/program/with/Trial/Master/File/to/archive/all/relevant/documents/in/align/with/Novartis/SOPs/Evaluate/requests/to/research/fund/as/they/pertain/to/Medical/Affairs/activities/职能/类别/药品/市场/推广/市场推广/经理/分享/微信/邮件/制药/生物/工程/生物工程/山德士/瑞士/诺华/集团/公司/子公司/诺华/集团/世界/第三/制药/公司/世界/500/强/企业/全球/唯一/专利/药/专利/非专利/药/疫苗/处方/方药/处方药/非处方药/业务/拥有/领导/地位/制药/公司/诺华/集团/成立/1996/年/瑞士/两家/具有/百年/历史/世界/著名/制药/公司/汽巴/嘉基/山德士/合并/而成/山德士/主要/从事/专利/非专利/药品/研发/生产/销售/业务/涵盖/原料/原料药/制剂/生物/制品/生物制品/拥有/950/多个/化合/化合物/5000/多种/制剂/全球/第二/专利/非专利/药/公司/山德士/中国/2007/年/月/正式/开展/中国/业务/当年/12/月/20/日向/德国/格兰泰/公司/收购/位于/中山/中山市/火炬/区/健康/基地/中山/格兰泰/制药/中山/成立/山德士/中国/制药/有限/公司/有限公司/注册/资金/注册资金/2200/美元/万美元/投资/总额/投资总额/达/3500/美元/万美元/
